PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see F	Form PCT/ISA/220
10589-13-228		re applicable, item 5 below.
International application No. PCT/US04/09572	International filing date (day/month/year) 26 March 2004 (26.03.2004)	(Earliest) Priority Date (day/month/year) 27 March 2003 (27.03.2003)
Applicant PTC THERAPEUTICS, INC.		
This international search report consists It is also accompanied	prepared by this International Searching Autle transmitted to the International Bureau. of a total of sheets. I by a copy of each prior art document cited in	
Basis of the Report With regard to the language, the	e international search was carried out on the bas unless otherwise indicated under this item.	is of the international application in the
The international	l search was carried out on the basis of a transla rity (Rule 23.1(b)).	ation of the international application
b. With regard to any nucleoti	de and/or amino acid sequence disclosed in the	ne international application, see Box No. I.
2. Certain claims were found	unsearchable (See Box No. II)	
3. Unity of invention is lacking	ıg (See Box No. III)	
4. With regard to the title,	·	
the text is approved as subm	uitted by the applicant.	
the text has been established	by this Authority to read as follows:	
5. With regard to the abstract,		
the text is approved as submi	tted by the applicant.	
the text has been established, may, within one month from	, according to Rule 38.2(b), by this Authority as the date of mailing of this international search r	it appears in Box No. IV. The applicant eport, submit comments to this Authority.
6. With regard to the drawings,		1
	ublished with the abstract is Figure No.	
as suggested by the a	••	
	uthority, because the applicant failed to suggest	
as selected by this At	uthority, because this figure better characterizes	the invention.
b. none of the figures is to be pu	blished with the abstract.	

Form PCT/ISA/210 (first sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/09572

	ox No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet			
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1.		Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:		
2.	\boxtimes	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically. Please See Continuation Sheet		
3.	\boxtimes	Claims Nos.: 35 and 52 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
Box	No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)		
		onal Searching Authority found multiple inventions in this international application, as follows: ontinuation Sheet		
1. 2. 3.		As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:		
4. [i r k on Pro	No required additional search fees: were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: Otest The additional search fees were accompanied by the applicant's protest.		
	_ 2	No protest accompanied the payment of additional search fees.		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/09572

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A01N 61/00; C12Q 1/00; G01N 33/566, 573 AND 574					
US CL	: 435/4, 6, 7.2, 7.21, 41, 69.2, 91.3, 183; 514/1		·s .:		
	o International Patent Classification (IPC) or to both r	national clas	ssification and IPC		
	DS SEARCHED				
	ocumentation searched (classification system followers 35/4, 6, 7.2, 7.21, 41, 69.2, 91.3, 183; 514/1, 2	d by classifi	cation symbols)		
Documentati	ion searched other than minimum documentation to the	ne extent the	at such documents are included	in the fields searched	
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet					
	UMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where			Relevant to claim No.	
X	US 6,446,032 B1 (SCHIMMEL) 03 September 200)2, see entir	e patent document.	33, 34, 36-39, 53, 54	
<u>x</u>	WO 02/083837 A1 (ALMSTEAD) 24 October 200: abstract, examples and claims.	2, see entire	e document, especially the	33, 34, 36-39, 53, 54	
Y	dosinaci, examples and citalis.			1-32 and 40-51	
x	WO 02/083953 A1 (PTC THERAPEUTICS) 24 October		see entire document,	33, 34, 36-39, 53, 54	
Y	especially the abstract, examples and claims.			1-32, 40-51	
Y	WANG, M.J. et al. Substrate Masking: Binding of Nuclease Results in Artifactual Inhibition of RNA I Research, 1990, Vol. 18, No. 22, pages 6625-6631, abstract, pages 6625-6626, bridging paragraph, pag paragraph 8.	Processing F see entire p	Reactions. Nucleic Acids bublication, especially the	1-34, 36-51, 53, 54	
Y	LI, H. et al. Crystal Structure and Evolution of a Transport April 1998, Vol. 280, No. 10, pages 279-284, see en			1-34, 36-51, 53, 54	
Further	documents are listed in the continuation of Box C.		See patent family annex.		
* S	pecial categories of cited documents:	"T"	later document published after the interne		
"A" document particular	defining the general state of the art which is not considered to be of relevance		and not in conflict with the application bu principle or theory underlying the invention		
"E" earlier app	"X" document of particular relevance; the claimed invention cannot be carlier application or patent published on or after the international filing date considered novel or cannot be considered to involve an inventive step when the document is taken alone				
	which may throw doubts on priority claim(s) or which is cited to he publication date of another citation or other special reason (as	"Y" ·	document of particular relevance; the clair considered to involve an inventive step w with one or more other such documents, s	hen the document is combined	
"O" document	referring to an oral disclosure, use, exhibition or other means		to a person skilled in the art		
	P" document published prior to the international filing date but later than the "&" document member of the same patent family priority date claimed				
Date of the ac	Date of the actual completion of the international search Date of mailing of the international search report				
04 April 2005	(04.04.2005)	_	JUN 20 05		
1 1 11 Cd TOA #10				~ 10 D.	
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450			Shibuya 1000 100	arrofa	
Alex	andria, Virginia 22313-1450	Telephone	No. (571) 272-1600		
acsimile No. (703) 305-3230					

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/09572

tegory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	HYDE-DERUYSCHER, R. et al. Detection of Small-Molecule Enzyme Inhibitors with Peptides Isolated from Phage-Displayed Combinatorial Peptide Libraries. Chemistry & Biology, 2000, Vol. 7, pages 17-25, see entire article, especially the abstract, Table I and pages 23-24.	1-34, 36-51, 53, 5
Y	ABELSON, J. et al. tRNA Splicing. Journal of Biological Chemistry, May 1998, Vol. 273, No. 21, pages 12685-12688, see entire article.	1-34, 36-51, 53, 5
Y	TROTTA, C.R. et al. The Yeast tRNA Splicing Endonuclease: A Tetrameric Enzyme with Two Active Site Subunits Homologous to the Archaeal tRNA Endonuclease. Cell, June 1997, Vol. 89, pages 849-858, see entire article.	1-34, 36-51, 53, 5
Y	VAUGHAN, M.D. et al. Methionine In and Out of Proteins: Targets for Drug Design. Current Medicinal Chemistry, 2002, Vol. 9, No. 3, pages 385-409, see entire article.	1-34, 36-51, 53, 5
x	WO 01/25486 A1 (UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY) 12	33, 34, 36-39, 53, 5
	April 2001, see entire document, especially the abstract, examples and claims.	
Y		1-32, 40-51
	·	
.		
	· .	
ŀ		
	·	
ľ		
[

International application No. INTERNATIONAL SEARCH REPORT PCT/US04/09572 Continuation of Box II Reason 2: Claims 35 and 52 are multiple dependent claims that depend from claims 33 and 34, which are dependent from claim 12, which is a multiple dependent claim. Thus a multiple dependent claim (i.e., claim 12) serves as a basis for claims 35 and 52, which are multiple dependent claims. Claims 35 and 52, therefore, are improper dependent claims, (see Rule 6.4 (a)). BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid. Group I, claim(s) 1-32 and 40-51, drawn to methods for identifying a compound that modulates animalia tRNA splicing endonuclease activity. Group II, claim(s) 33, 34, 36-39, 53, and 54, drawn to methods of preventing, treating, managing or ameliorating a proliferative disorder by administering an antiproliferative compound identified by the Group I method. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the methods of Groups I and II are distinctly different methods drawn to different method objectives. The antiproliferative compounds of Group II and derived from the

Group I methods do not represent a "special" technical feature because antiproliferative compounds are known in the art. See e.g., WO

Continuation of B. FIELDS SEARCHED Item 3: WEST: PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD. STN: CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS.

02/083953A1; WO 02/083837A1; and WO 01/25486A1.